Chief Medical Officer
Dr. Pilgrim has extensive experience in leading the global development of drugs in a wide range of therapeutic areas including cardiology, neurology, psychiatry and inflammation. While at Glaxo she led the clinical program for Imitrex from phase 2-4 and through a series of line extensions. At Sanofi she oversaw the global approval of Plavix and initiated the major megatrials which were key to the successful commercialization of the drug. Dr Pilgrim has experience of leading drug development within both large integrated pharmaceutical companies, such as Glaxo, Sanofi and DuPont and within smaller and virtual companies including Elan, Avera and CoLucid. As a clinical pharmacologist at Beecham Pharmaceuticals she was responsible for a wide range of early clinical studies, including first-in-man, pharmacokinetics and efficacy modeling in healthy subjects. Dr Pilgrim trained as a scientist and physician at Oxford University in the UK, qualifying as a physician and gaining a doctorate in development neurobiology.
In her capacity as Chief Medical Officer, Alison is responsible for overseeing the design and execution of CoLucid's clinical development plan.
